| Literature DB >> 22506106 |
Tinashe Mudzviti1, Charles C Maponga, Star Khoza, Qing Ma, Gene D Morse.
Abstract
Background. The main objective was to determine the impact of herbal drug use on adverse drug reactions in patients on antiretroviral therapy (ART). Methodology. Patients receiving first-line ART from the national roll-out program participated in this cross-sectional study. Participants were interviewed and a data collection sheet was used to collect information from the corresponding medical record. Results. The majority (98.2%) of participants were using at least one herbal drug together with ART. The most common herbal remedies used were Allium Sativum (72.7%), Bidens pilosa (66.0%), Eucalyptus globulus (52.3%), Moringa oleifera (44.1%), Lippia javanica (36.3%), and Peltoforum africanum (34.3%). Two indigenous herbs, Musakavakadzi (OR = 0.25; 95% CI 0.076-0.828) and Peltoforum africanum (OR = 0.495; 95% CI 0.292-0.839) reduced the occurrence of adverse drug events. Conclusions. The use of herbal drugs is high in the HIV-infected population and there is need for pharmacovigilance programs to recognize the role they play in altering ADR profiles.Entities:
Year: 2012 PMID: 22506106 PMCID: PMC3313558 DOI: 10.1155/2012/434171
Source DB: PubMed Journal: AIDS Res Treat ISSN: 2090-1240
Demographic and clinical characteristics of study patients. Unless specified, figures represent frequencies and percentages.
| Characteristic |
| % |
|---|---|---|
| Age (mean ± SD) | 40.8 | 9.2 |
| Gender | ||
| Male | 137 | 35.3 |
| Female | 251 | 64.7 |
| Comorbidities | ||
| Diabetes mellitus | 5 | 1.3 |
| Hypertension | 67 | 17.3 |
| Anaemia | 34 | 8.8 |
| Asthma | 21 | 5.4 |
| Epilespy | 4 | 1.0 |
| Malaria | 155 | 40.0 |
| Tuberculosis | 131 | 33.8 |
| Shingles | 125 | 32.2 |
| ARV regimen | ||
| AZT/3TC/EFV | 10 | 2.6 |
| AZT/3TC/NVP | 36 | 9.3 |
| D4T/3TC/EFV | 12 | 3.1 |
| D4T/3TC/NVP | 330 | 85.1 |
| Number of herbs per patient (mean ± SD) | 7.9 | 4.4 |
Frequencies of herbal use in study population.
| Characteristic |
| % |
|---|---|---|
|
| 41 | 10.6 |
|
| 103 | 26.6 |
|
| 108 | 27.8 |
|
| 171 | 44.1 |
|
| 62 | 16.0 |
|
| 13 | 3.4 |
|
| 15 | 3.9 |
|
| 256 | 66.0 |
|
| 141 | 36.3 |
|
| 133 | 34.3 |
|
| 30 | 7.7 |
|
| 41 | 10.6 |
|
| 203 | 52.3 |
|
| 282 | 72.7 |
†Scientific names could not be identified for these formulations
Prevalence of adverse drug reactions in the study patients.
| ADR type and severity |
| % |
|---|---|---|
| ADR prevalence | 273 | 70.4 |
| ADR severity ( | ||
| Grade 1 | 161 | 41.5 |
| Grade 2 | 96 | 24.7 |
| Grade 3 | 15 | 3.9 |
| Grade 4 | 1 | 0.3 |
| Type of ADRs | ||
| Peripheral neuropathy | 162 | 41.8 |
| Skin rash | 101 | 26.0 |
| Lipodystrophy | 13 | 3.4 |
| GI symptoms | 28 | 7.2 |